Jubilant Pharmova Balance Sheet Health
Financial Health criteria checks 4/6
Jubilant Pharmova has a total shareholder equity of ₹59.3B and total debt of ₹28.3B, which brings its debt-to-equity ratio to 47.7%. Its total assets and total liabilities are ₹119.2B and ₹60.0B respectively. Jubilant Pharmova's EBIT is ₹6.6B making its interest coverage ratio 2.8. It has cash and short-term investments of ₹10.8B.
Key information
47.7%
Debt to equity ratio
₹28.25b
Debt
| Interest coverage ratio | 2.8x |
| Cash | ₹10.77b |
| Equity | ₹59.27b |
| Total liabilities | ₹59.97b |
| Total assets | ₹119.24b |
Recent financial health updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Financial Position Analysis
Short Term Liabilities: JUBLPHARMA's short term assets (₹35.0B) exceed its short term liabilities (₹19.5B).
Long Term Liabilities: JUBLPHARMA's short term assets (₹35.0B) do not cover its long term liabilities (₹40.5B).
Debt to Equity History and Analysis
Debt Level: JUBLPHARMA's net debt to equity ratio (29.5%) is considered satisfactory.
Reducing Debt: JUBLPHARMA's debt to equity ratio has reduced from 85.8% to 47.7% over the past 5 years.
Debt Coverage: JUBLPHARMA's debt is well covered by operating cash flow (27.2%).
Interest Coverage: JUBLPHARMA's interest payments on its debt are not well covered by EBIT (2.8x coverage).